These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27702550)

  • 1. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
    Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
    Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
    Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
    Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
    D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
    PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
    Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
    J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
    Giustiniani J; Marie-Cardine A; Bensussan A
    J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.
    Ortonne N; Ram-Wolff C; Giustiniani J; Marie-Cardine A; Bagot M; Mecheri S; Bensussan A
    J Invest Dermatol; 2011 Apr; 131(4):916-24. PubMed ID: 21191401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.
    Abecassis S; Giustiniani J; Meyer N; Schiavon V; Ortonne N; Campillo JA; Bagot M; Bensussan A
    J Invest Dermatol; 2007 May; 127(5):1161-6. PubMed ID: 17218942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.
    Rodriguez-Barbosa JI; Fernandez-Renedo C; Moral AMB; Bühler L; Del Rio ML
    Cell Mol Immunol; 2017 Jun; 14(6):497-510. PubMed ID: 26924526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD160: a unique activating NK cell receptor.
    Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
    Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
    Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
    Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of murine CD160+ CD8+ T lymphocytes.
    Tsujimura K; Obata Y; Matsudaira Y; Nishida K; Akatsuka Y; Ito Y; Demachi-Okamura A; Kuzushima K; Takahashi T
    Immunol Lett; 2006 Jul; 106(1):48-56. PubMed ID: 16764942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
    Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
    Front Immunol; 2018; 9():2611. PubMed ID: 30483269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B- and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity.
    del Rio ML; Kurtz J; Perez-Martinez C; Ghosh A; Perez-Simon JA; Rodriguez-Barbosa JI
    Transplantation; 2011 Nov; 92(10):1085-93. PubMed ID: 21978997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic implications of NK cell regulation of allogeneic CD8 T cell-mediated immune responses stimulated through the direct pathway of antigen presentation in transplantation.
    Rodriguez-Barbosa JI; Ferreras MC; Buhler L; Jones ND; Schneider P; Perez-Simon JA; Del Rio ML
    MAbs; 2018 Oct; 10(7):1030-1044. PubMed ID: 30036156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.